The role of the redox protein thioredoxin in cell growth and cancer

Free Radical Biology and Medicine

Volumn 29, Issue 3-4, 2000, Pages 312-322

  Powis, Garth ^a   Mustacich, Debbie ^a   Coon, Amy ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Apoptosis; Cancer; Cell growth; Free radicals; Redox control; Thioredoxin

Indexed keywords

FREE RADICAL; THIOREDOXIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CARCINOGENESIS; CELL GROWTH; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW;

MAMMALIA;

EID: 0033796101     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00313-0     Document Type: Article

References (120)

1. Laurent T.C., Moore E.C., Reichard P. Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239:1964;3436-3444.
2. Moore E.C. A thioredoxin-thioredoxin reductase system from rat tumor. Biochem. Biophys. Res. Commun. 29:1967;264-268.
3. Wakasugi H., Rimsky L., Mahe Y., Kamel A.M., Fradelizi D., Tursz T., Bertogio J. Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor. Proc. Natl. Acad. Sci. USA. 84:1987;804-808.
4. Clarke F.M., Orozco C., Perkins A.V., Cock I., Tonissen K.F., Robins A.J., Wells J.R. Identification of molecules involved in the "early pregnancy factor" phenomenon. J. Reprod. Fertil. 93:1991;525-539.
5. Deiss L.P., Kimchi A. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal. Science. 252:1991;117-120.
6. Gasdaska P.Y., Oblong J.E., Cotgreave I.A., Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF) thioredoxin mRNA is elevated in some human tumors . Biochim. Biophys. Acta. 1218:1994;292-296.
7. Silberstein D.S., McDonough S., Minkoff M.S., Balcewicz-Sablinska M.K. Human eosinophil cytotoxicity-enhancing factor. J. Biol. Chem. 268:1993;9138-9142.
8. Gladyshev V.N., Jeang K., Stadtman T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA. 93:1996;6146-6151.
9. Powis G., Gasdaska J.R., Gasdaska P.Y., Berggren M., Kirkpatrick D.L., Engman L., Cotgreave I.A., Angulo M., Baker A. Selenium and the thioredoxin redox system effects on cell growth and death . Oncol. Res. 9:1997;303-312.
10. Gasdaska J.R., Gasdaska P.Y., Gallegos A., Powis G. Human thioredoxin reductase gene localization to chromosomal position 12q23→q24.1 and mRNA distribution in human tissue. Genomics. 37:1996;257-259.
11. Zhong L., Arner E.S.J., Ljung J., Aslund F., Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J. Biol. Chem. 273:1998;8581-8591.
12. Gasdaska P.Y., Gasdaska J.R., Cochran S., Powis G. Cloning and sequencing of human thioredoxin reductase. FEBS Lett. 373:1995;5-9.
13. Gasdaska P.Y., Berggren M.M., Berry M.J., Powis G. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett. 442:1999;105-111.
14. Lee S., Kim J., Kwon K., Yoon H.W., Levine R.L., Ginsburg A., Rhee S.G. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J. Biol. Chem. 274:1999;4722-4734.
15. Miranda-Vizuete A., Damdimopoulos A.E., Pedrajas J.R., Gustafsson J.-A., Spyrou G. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization . Eur. J. Biochem. 261:1999;405-411.
16. Gotoh, S.; Terashima, H.; Yagi, K.; Mizoguchi, T. Cloning and sequence of bovine thioredoxin cDNA. GenBank. National Center for Biotechnology Information. Accession number AF104105. 1998. Available at: http://www.ncbi.nlm.nih.gov/Genbank.
17. Matsui M., Taniguchi Y., Hirota K., Taketo M., Yodoi J. Structure of the mouse thoiredoxin-encoding gene and its processed pseudogene. Gene. 152:1995;165-171.
18. Kaghad M., Dessarps F., Jacquemin-Sablon H., Caput D., Fradelizi D., Wollman E.E. Genomic cloning of human thioredoxin-encoding gene mapping of the transcription start point and analysis of the promoter . Gene. 140:1994;273-278.
19. Heppell-Parton A., Cahn A., Bench A., Lowe N., Lehrach H., Zehetner G., Rabbitts P. Thioredoxin, a mediator of growth inhibition, maps to 9q31. Genomics. 26:1995;379-381.
20. Miranda-Vizuete, A. Human thioredoxin 1 pseudogene 2. GenBank. National Center for Biotechnology Information. Accession number AF146024. 1999. Available at: http://www.ncbi.nlm.nih.gov/Genbank.
21. Wollman E.E., d'Auriol L., Rimsky L., Shaw A., Jacquot J., Wingfield P., Graber P., Dessarps F., Robin P., Galibert F., Bertoglio J., Fradelizi D. Cloning and expression of cDNA for human thioredoxin. J. Biol. Chem. 263:1988;15506-15512.
22. Weichsel A., Gasdaska J.R., Powis G., Montfort W.R. Crystal structures of reduced, oxidized, and mutated human thioredoxins evidence for a regulatory homodimer . Structure. 4:1996;735-751.
23. + T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int. Immunol. 7:1995;625-633.
24. Hariharan J., Hebbar P., Ranie J., Philomena; Sinha A.M., Datta S. Alternative forms of the human thioredoxin mRNA identification and characterization . Gene. 173:1996;265-270.
25. Spyrou G., Enmark E., Miranda-Vizuete A., Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem. 272:1997;2936-2941.
26. Miranda-Vizuete, A.; Gustafsson, J.-A.; Spyrou, G. Human mitochondrial thioredoxin. GenBank. National Center for Biotechnology Information. Accession number HSU78678.1. 1999. Available at: http://www.ncbi.nlm.nih.gov/Genbank.
27. Miranda-Vizuete A., Gustafsson J., Spyrou G. Molecular cloning and expression of a cDNA encoding a human thioredoxin-like protein. Biochem. Biophys. Res. Commun. 243:1998;284-288.
28. Lee K., Murakawa M., Takahashi S., Tsubuki S., Kawashima S., Sakamaki K., Yonehara S. Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa. J. Biol. Chem. 273:1998;19160-19166.
29. Balcewicz-Sablinska M.K., Wollman E.E., Gort R., Silberstein D.S. Human eosinophil cytotoxicity-enhancing factor II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor. J. Immunol. 147:1991;2170-2174.
30. Qin J., Clore G., Gronenborn A. The high-resolution three-dimensional solution structures of the oxidized and reduced state of human thioredoxin. Structure. 2:1994;502-522.
31. Katti S.K., LeMaster D.M., Eklund H. Crystal structure of thioredoxin from Escherichia coli at 1.68 Å resolution. J. Mol. Biol. 212:1990;167-184.
32. Holmgren A., Soderberg B.-O., Eklund H., Branden C.-I. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 Å resolution. Proc. Natl. Acad. Sci. USA. 72:1975;2305-2309.
33. Jeng M.F., Campbell A., Begley T., Holmgren A., Case D., Wright P., Dyson H. High-resolution solution structures of oxidized and reduced Escherichia coli thioredoxin. Structure. 2:1994;853-868.
34. Eklund H., Gleason F., Holmgren A. Structural and functional relations among thioredoxins of different species. Proteins. 11:1991;13-28.
35. Holmgren A. Thioredoxin structure and mechanism conformational changes on oxidation of the active-site sulfhydryls to a disulfide . Structure. 3:1995;239-243.
36. Ren X., Bjornstedt M., Shen B., Ericson M.L., Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry. 32:1993;9701-9705.
37. 73→ Ser mutation. Biochem. Pharmacol. 52:1996;1741-1747.
38. Andersen J.F., Sanders D.A.R., Gasdaska J.R., Weichsel A., Powis G., Montfort W.R. Human thioredoxin homodimers regulation of pH, role of aspartate 60, and crystal structure of the aspartate 60 → asparagine mutant . Biochemistry. 36:1997;13979-13988.
39. Gronenborn A.M., Clore G.M., Louis J.M., Wingfield P.T. Is human thioredoxin monomeric or dimeric? Protein Sci. 8:1999;426-429.
40. Holmgren A., Luthman M. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay. Biochemistry. 17:1978;4071-4077.
41. Grogan T., Fenoglio-Priser C., Zaheb R., Bellamy W., Vela E., Richter L., Powis G. Overexpression of thioredoxin, a putative oncogene, in gastric carcinoma with associated change in proliferation and apoptosis. Human Path. 31:2000;475-481.
42. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA. 94:1997;3633-3638.
43. Makino Y., Yoshikawa N., Okamoto K., Hirota K., Yodoi J., Makino I., Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J. Biol. Chem. 274:1999;3182-3188.
44. Masutani H., Hirota K., Sasada T., Ueda-Taniguchi Y., Taniguchi Y., Sono H., Yodoi J. Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I tax. Immunol. Lett. 54:1996;67-71.
45. Imamoto N., Kamei Y., Yoneda Y. Nuclear transport factors function, behavior and interaction . Eur. J. Histochem. 42:1998;9-20.
46. Martin H., Dean M. Identification of a thioredoxin-related protein associated with plasma membranes. Biochem. Biophys. Res. Commun. 175:1991;123-128.
47. Wakasugi N., Tagaya Y., Wakasugi A., Mitsui M., Maeda M., Yodoi J., Tursz T. Adult T-cell leukemia-derived factor/thioredoxin produced by both human T-lymphotropic virus type 1and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2. Proc. Natl. Acad. Sci. USA. 87:1990;8282-8286.
48. Ericson M.L., Horling J., Wendel-Hansen V., Holmgren A., Rosen A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res. 11:1992;201-207.
49. Nakamura H., Masutani H., Tagaya Y., Yamauchi A., Inamoto T., Nanbu Y., Fujii S., Ozawa K., Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor a human thioredoxin homologue in hepatocellular carcinoma . Cancer. 69:1992;2091-2097.
50. Ericson M.L., Hörling J., Wendel-Hansen V., Holmgren A., Rosen A. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res. 11:1992;201-207.
51. Rubartelli A., Bajetto A., Allavena G., Wollman E., Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J. Biol. Chem. 267:1992;24161-24164.
52. Hori K., Katayama M., Sato N., Ishii K., Waga S., Yodoi J. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX). Brain Res. 652:1994;304-310.
53. Rubartelli A., Bonifaci N., Sitia R. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res. 55:1995;675-680.
54. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:1996;3459-3466.
55. Rubartelli A., Sitia R. Interleukin Iβ and thioredoxin are secreted through a novel pathway of secretion. Biochem. Soc. Trans. 19:1991;255-259.
56. Oblong J.E., Berggren M., Gasdaska P.Y., Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem. 269:1994;11714-11720.
57. Powis G., Gasdaska J.R., Baker A. Redox signalling and the control of cell growth and death. Adv. Pharmacol. 38:1997;329-359.
58. Gasdaska J.R., Berggren M., Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 6:1995;1643-1650.
59. Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., Brown N., Arai K.-I., Yokota T., Wakasugi H., Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin possible involvement of dithiol-reduction in the IL-2 receptor induction . EMBO J. 8:1989;757-764.
60. Tagaya Y., Okada M., Sugie K., Kasahara T., Kondo N., Hamuro J., Matsushima K., Dinarello C.A., Yodoi J. IL-2 receptor(p55)/TAC-inducing factor purification and characterization of adult T cell leukemia-derived factor. J. Immunol. 140:1988;2614-2620.
61. Schenk H., Vogt M., Droge W., Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J. Immunol. 156:1996;765-771.
62. cdc2 kinase activation in mouse two-cell block. Biochim. Biophys. Acta. 1176:1993;90-94.
63. Fujii S., Nanbu Y., Konishi I., Mori T., Masutani H., Yodoi J. Immunohistochemical localization of adult T-cell leukaemiaderived factor, a human thioredoxin homologue, in human fetal tissues. Virchows Arch. A. Pathol. Anat. Histopathol. 419:1991;317-326.
64. Matsui M., Oshima M., Oshima H., Takaku K., Maruyama T., Yodoi J., Taketo M.M. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Devel. Biol. 178:1996;179-185.
65. 2 upon thioredoxin-enriched lens epithelial cells. J. Biol. Chem. 263:1988;4984-4990.
66. Bjornstedt M., Xue J., Huang W., Akesson B., Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J. Biol. Chem. 269:1994;29382-29384.
67. Das K.C., Lewis-Molock Y., White C.W. Elevation of manganese superoxide dismutase gene expression by thioredoxin. Am. J. Respir. Cell Mol. Biol. 17:1997;713-726.
68. McAndres J., Patel R.P., Jo H., Cornwell T., Lincoln T., Moellering D., White C.R., Matalon S., Darley-Usmar V. The interplay of nitric oxide and peroxynitrite with signal transduction pathways implications for disease . Semin. Perinatol. 21:1997;351-366.
69. Patel J.M., Zhang J., Block E.R. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols role of thioredoxin in regulation of catalytic activity . Am. J. Respir. Cell Mol. Biol. 15:1996;410-419.
70. Zhang J., Li Y.D., Jawaharlal M.P., Block E.R. Thioredoxin overexpression prevents NO-induced reduction of NO synthase activity in lung endothelial cells. Am. J. Physiol. 275:1998;L288-L293.
71. Jordan A., Reichard P. Ribonucleotide reductases. Ann. Rev. Biochem. 67:1998;71-98.
72. Hopper S., Iurlano D. Properties of a thioredoxin purified from rabbit bone marrow which fails to serve as a hydrogen donor for the homologous ribonucleotide reductase. J. Biol. Chem. 258:1983;13453-13457.
73. Mau B., Powis G. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Biochem. Pharmacol. 43:1992;1621-1626.
74. Gilmore T.D., Koedood M., Piffat K.A., White D.W. Rel/NF-κB/IκB proteins and cancer. Oncogene. 11:1997;1367-1378.
75. Moore B.E., Bose H.R.J. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology. 162:1988;377-387.
76. Tolendano M.B., Leonard W.J. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA. 88:1991;4328-4332.
77. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor κB involvement of a cellular reducing catalyst thioredoxin . J. Biol. Chem. 268:1993;11380-11388.
78. Hasegawa-Sasaki J. Early changes in inositol lipids and their metabolites induced by platelet-derived growth factor in quiescent Swiss mouse 3T3 cells. Biochem. J. 232:1985;99-109.
79. Sorachi K., Sugie K., Maekawa N., Takami M., Kawabe T., Kumagai S., Imura H., Yodoi J. Induction and function of FcERII on YT cells; possible role of ADF/thioredoxin in FcERII expression. Immunobiology. 185:1992;193-206.
80. Galter D., Mihm S., Dröge W. Distinct effects of glutathione disulfide on the nuclear transcription factors κB and the activator protein-1. Eur. J. Biochem. 221:1994;639-648.
81. Matthews J.R., Wakasugi N., Virelizier J.-L., Yodoi J., Hay R.T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 20:1992;3821-3830.
82. Ghosh G., Duyne G.V., Ghosh S., Sigler P.B. The structure of NFκB p50 homodimer bound to a κB site. Nature. 373:1995;303-310.
83. Muller G.W., Rey F.A., Sodeoka M., Verdine G.L., Harrison S.C. Structure of the NF-κB homodimer bound to DNA. Nature. 373:1995;311-317.
84. Qin J., Clore G.M., Kennedy W.P., Hutch J.R., Gronenborn A.M. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-κB. Structure. 3:1994;289-297.
85. Freemerman A.J., Gallegos A., Powis G. NF-κB transactivation is increased but not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 59:1999;4090-4094.
86. Schenk H., Klein M., Erdbrügger W., Dröge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc. Natl. Acad. Sci. USA. 91:1994;1672-1676.
87. Chakraborti P.K., Garabedian M.J., Yamamoto K.R., Simons S.S. Jr. Role of cysteines 640, 656, and 661 in steroid binding to rat glucocorticoid receptors. J. Biol. Chem. 267:1992;11366-11373.
88. Hutchison K.A., Matic G., Meshinchi S., Bresnick E.H., Pratt W.B. Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor. J. Biol. Chem. 266:1991;10505-10509.
89. Makino Y., Okamoto K., Yoshikawa N., Aoshima M., Hirota K., Yodoi J., Umesono K., Makino I., Tanaka H. Thioredoxin a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system . J. Clin. Invest. 98:1996;2469-2477.
90. Grippo J.F., Tienrungroj W., Dahmer M.K., Housley P.R., Pratt W.B. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J. Biol. Chem. 258:1983;13658-13664.
91. 2 and antioxidants have opposite effects on activation of NF-κ B and AP-1 in intact cells AP-1 as secondary antioxidant-responsive factor . EMBO J. 12:1993;2005-2015.
92. Abate C., Patel L., Rauscher F.J. III, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 249:1990;1157-1161.
93. Xanthoudakis S., Miao G.G., Curran T. The redox and DNA-repair activities of ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA. 91:1994;23-27.
94. Huan Y., Domann F.E. Redox modulation of AP-2 DNA binding activity in vitro. Biochem. Biophys. Res. Commun. 249:1998;307-312.
95. Iwata S., Hori T., Sato N., Hirota K., Sasada T., Mitsui A., Hirakawa T., Yodoi J. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state . J. Immunol. 158:1997;3108-3117.
96. Baker A., Payne C.M., Briehl M.M., Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibitis apoptosis in vitro and in vivo. Cancer Res. 57:1997;5162-5167.
97. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18). Nature. 349:1991;254-256.
98. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17:1998;2596-2606.
99. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94.
100. Tobiume K., Inage T., Takeda K., Enomoto S., Miyazono K., Ichijo H. Molecular cloning and characterization of the mouse apoptosis signal-regulating kinase 1. Biochem. Biophys. Res. Commun. 239:1997;905-910.
101. Lee K., Murakawa M., Nishida E., Tsubuki S., Kawashima S., Sakamaki K., Yonehara S. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene. 16:1998;3029-3037.
102. Wang J., Kobayashi M., Sakurada K., Imamura M., Moriuchi T., Hosokawa M. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin. Blood. 89:1997;2480-2487.
103. Kunkel M.W., Kirkpatrick D.L., Johnson J.I., Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signalling as potential anticancer drugs. Anticancer Drug Des. 12:1997;659-670.
104. Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M., Kohno K., Takenaka K., Sugimachi K., Kuwano M. Enhanced coexpression of thioredixin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 56:1996;5330-5333.
105. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin and etoposide. Cancer Res. 55:1995;4293-4296.
106. Yamada M., Tomida A., Yoshikawa H., Taketani Y., Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res. 2:1996;427-432.
107. Yamada M., Tomida A., Yoshikawa H., Taketani Y., Tsuruo T. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human avarian and colon cancer cell lines. Cancer Chemother. Pharmacol. 40:1997;31-37.
108. Sasada T., Iwata S., Sato N., Kitaoka Y., Hirota K., Nakamura K., Nishiyama A., Taniguchi Y., Takabayashi A., Yodoi J. Redox control of resistance to cis-diamminedichloroplatinum(II) (CDDP) protective effect of human thioredoxin against CDDP-induced cytotoxicity . J. Clin. Invest. 97:1996;2268-2276.
109. Takai Y., Kikkawa U., Kaibuchi K., Nishizuka Y. Membrane phospholipid metabolism and signal transduction for protein phosphorylation. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 18:1984;119-158.
110. Fujii S., Nanbu Y., Nonogaki H., Konishi I., Mori T., Masutani H., Yodoi J. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer. 68:1991;1583-1591.
111. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., Vogelstein B., Kinzler K.W. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
112. Miyazaki K., Noda N., Okada S., Hagiwara Y., Miyata M., Sakurabayashi I., Yamaguchi N., Sugimura T., Terada M., Wakasugi H. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy. 11:1998;277-288.
113. Nakamura H., DeRosa S., Roedere M., Anderson M.T., Dubs J.G., Yodoi J., Holmgren A., Herzenberg L.A. Elevation of plasma thioredoxin levels in HIV infected individuals. Int. Immunol. 8:1996;603-611.
114. Nakamura H., Vaage J., Valen G., Padilla C.A., Bjornstedt M., Holmgren A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic. Biol. Med. 24:1998;1176-1186.
115. Das K.C., White C.W. Detection of thioredoxin in human serum and biological samples using a sensitive sandwich ELISA with digoxigenin-labeled antibody. J. Immunol. Methods. 211:1998;9-20.
116. Kogaki H., Fujiwara Y., Yoshiki A., Kitajima S., Tanimoto T., Mitsui A., Shimamura T., Hamuro J., Ashihara Y. Sensitive enzyme-linked immunosorbent assay for adult T-cell leukemia-derived factor and normal value measurement. J. Clin. Lab. Anal. 10:1996;257-261.
117. Oblong J.E., Chantler E.L., Gallegos A., Kirkpatrick D.L., Chen T., Marshall N., Powis G. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother. Pharmacol. 34:1994;434-438.
118. Powis G., Kirkpatrick D.L., Angulo M., Gasdaska J.R., Powell M.B., Salmon S.E., Montfort W.R. Thioredoxin redox signalling a novel target for anticancer drug development . Anticancer Drugs. 7:(Suppl 3):1996;121-126.
119. Wakita H., Yodoi J., Masutani H., Toda K., Takigawa M. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions. J. Invest. Dermatol. 99:1992;101-107.
120. Freemerman A.J., Grallegos A., Powis G. Nuclear factor κB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 89:1999;4090-4094.